Barrington Research Downgrades LeMaitre Vascular (NASDAQ:LMAT) to Market Perform

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by Barrington Research from an “outperform” rating to a “market perform” rating in a report released on Friday, Marketbeat Ratings reports. Barrington Research also issued estimates for LeMaitre Vascular’s Q3 2025 earnings at $0.57 EPS, Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.30 EPS, Q1 2026 earnings at $0.60 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.65 EPS, Q4 2026 earnings at $0.68 EPS and FY2026 earnings at $2.62 EPS.

LMAT has been the subject of several other research reports. Oppenheimer reiterated an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price for the company. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus target price of $95.25.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT opened at $91.85 on Friday. The company has a market cap of $2.07 billion, a P/E ratio of 50.19, a P/E/G ratio of 2.22 and a beta of 0.96. The stock’s 50-day moving average is $96.89 and its 200-day moving average is $94.73. LeMaitre Vascular has a 52-week low of $62.39 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49. The company had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. As a group, equities analysts predict that LeMaitre Vascular will post 1.94 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its stake in LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 293 shares during the period. CBIZ Investment Advisory Services LLC lifted its stake in LeMaitre Vascular by 38.5% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 117 shares during the period. KBC Group NV lifted its stake in LeMaitre Vascular by 58.4% during the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 410 shares during the period. Huntington National Bank lifted its stake in LeMaitre Vascular by 64.9% during the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier’s stock worth $107,000 after purchasing an additional 455 shares during the period. Finally, Empowered Funds LLC acquired a new stake in shares of LeMaitre Vascular during the fourth quarter worth approximately $150,000. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.